Leaflet MITOMICINA MEDAC 40mg powder+solvent for intravesical solution


Indicated for: cancer

Route of administration: intravesical

Substance: mitomycin (antineoplastic agent)

ATC: L01DC03 (Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Other cytotoxic antibiotics)

Precautions:
Fertility warning
Fertility warning

This medicine may affect fertility.

Dose adjustment in hepatic impairment
Dose adjustment in hepatic impairment

Dose adjustment may be needed in liver disease.

Cytotoxic / special handling
Cytotoxic / special handling

Handle with special care.

Contraception required
Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding
Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis
Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring
Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Severe skin reactions
Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Mitomycin is a chemotherapy drug used for the treatment of certain types of cancer, including gastric cancer, pancreatic cancer, and bladder cancer. It acts as an alkylating agent, interfering with DNA synthesis in cancer cells and inhibiting their division.

The medication is administered intravenously or intravesically, depending on the type and location of the cancer. It is effective in reducing tumor size and slowing disease progression.

Side effects may include nausea, vomiting, bone marrow suppression, increased risk of infections, and, in rare cases, pulmonary or renal toxicity. Close monitoring is essential during treatment.

Consult your doctor to discuss the benefits and risks of treatment with Mitomycin. This medication must be administered under the supervision of an oncology specialist.

General data about MITOMICINA MEDAC 40mg

  • Substance: mitomycin
  • Date of last drug list: 01-09-2016
  • Commercial code: W62645004
  • Concentration: 40mg
  • Pharmaceutical form: powder+solvent for intravesical solution
  • Quantity: 6
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Concentrations available for mitomycin

  • 1mg/ml
  • 20mg
  • 40mg